Searched for
DRUG DELIVERY SOLUTIONS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- India’s quantum opportunity: Turning scale into strategic advantageIndia has a structural advantage in quantum computing. Its size inherently creates challenging optimisation issues, offering a practical te...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- How an Australian connection helped Shaily Mehrotra build a Rs 1,500-crore Indian skincare brandA gap in science-backed skincare products in the Indian market prompted Shaily Mehrotra to start Fixderma, with an aim to solve common skin...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- ET Most Innovative AI Product Awards 2026: Honouring the innovations powering India's next economyThe ET Most Innovative AI Product Awards 2026 brings together 11 distinct categories that reflect where artificial intelligence is deliveri...
- TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of IndiaTPG Growth is set to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, with Novo Holdings co-investing. This deal aim...
- US-based AptarGroup breaks ground for new pharma plant in Taloja, near MumbaiAptarGroup held a groundbreaking ceremony for a new pharmaceutical plant in Taloja, India. The facility expands AptarGroup's presence in th...
- Serum Institute buys 20% stake in IntegriMedicalSerum Institute of India acquires 20% stake in IntegriMedical for N-FIS drug delivery solution. Adar Poonawalla envisions a needle-free vac...
- BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution formIt is a more patient-friendly way to tackle prostate cancer. It can help improve patient compliance to a great extent, Badiger said. The co...
- ZIM Laboratories to list on NSE on FridayZIM Laboratories is a pharmaceutical company, focused on providing innovative drug delivery solutions that provide patient convenience and ...
- Everstone buys Mumbai-based drug tech firm Rubicon for Rs 220-croreThe India and Southeast Asia-focused Everstone has assets under management of USD3.3 billion and is headquartered in Singapore.
- Scientists develop drugs that disguise as human platelets to target cancerScientists have for the first time developed a technique that coats anticancer drugs in membranes made from patient's own platelets.
- 3M in talks to license drug delivery techUS-Based $23-billion diversified technology firm 3M is in talks with top domestic pharma companies to licence drug delivery technologies.
Load More
